Table 3 Analysis of factors predicting patient survival after SRS (Cox proportional hazards model)
Covariate (No. of patients) | MST (months) | P value | Hazard ratio (95% CI) |
|---|---|---|---|
Sex | 0.028 | 0.569 (0.344–0.942) | |
Female (37) | 8.9 | ||
Male (69) | 4.7 | ||
KPS | < .001 | 0.444 (0.279–0.706) | |
KPS ≥ 70 (56) | 9.7 | ||
KPS < 70 (50) | 4.5 | ||
Controlled systemic disease/no extracranial metastasis | < .001 | 0.361 (0.206–0.632) | |
Yes (25) | 18.0 | ||
No (81) | 4.7 | ||
Interval from primary diagnosis to SRS | 0.053 | 0.687 (0.448–1.05) | |
Long > 12 months (54) | 8.8 | ||
Short ≤ 12 months (52) | 4.4 | ||
Chemotherapy | 0.806 | 1.08 (0.603–1.92) | |
Yes (31) | 12.8 | ||
No (75) | 5.2 | ||
No. of metastases | 0.513 | 0.864 (0.557–1.34) | |
Solitary (52) | 6.9 | ||
Multiple (54) | 7.1 | ||
Cumulative PIV | 0.375 | 1.25 (0.762–2.06) | |
Small ≤ 5 mL (45) | 7.7 | ||
Large > 5 mL (61) | 5.4 | ||
Type of intervention | 0.269 | 1.47 (0.744–2.89) | |
Two-session (15) | 4.0 | ||
Single session (91) | 7.2 |